Last reviewed · How we verify
ChAdox1
At a glance
| Generic name | ChAdox1 |
|---|---|
| Sponsor | Makerere University |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- COVID-19
- Headache
- Injection site pain
- Fatigue
- Chills
- Pain
- Myalgia
- Pyrexia
- Hypertension
- Influenza
- Cough
- Arthralgia
Key clinical trials
- Effectiveness, Immunogenicity and Safety of the Second Booster Dose of the Vaccine Against COVID-19 in the Elderly
- Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1 (PHASE1, PHASE2)
- Combination Vaccination and Broadly Neutralising Antibody Therapy in HIV (PHASE2)
- Safety and Immunogenicity of a Candidate Rift Valley Fever Vaccine (RVF003) (PHASE2)
- Prime-boost Immunotherapeutic Trial in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer (PHASE1, PHASE2)
- The ARCT-154 Self-Amplifying RNA Vaccine Efficacy Study (ARCT-154-01) (PHASE2, PHASE3)
- Phase II/III Study of the AVX/COVID-12 Vaccine Against COVID-19 Applied as a Booster. (PHASE2, PHASE3)
- Phase II Study of AVX/COVID-12 Vaccine in Subjects With Prior SARS-CoV-2 Immunity Evidence (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ChAdox1 CI brief — competitive landscape report
- ChAdox1 updates RSS · CI watch RSS
- Makerere University portfolio CI